Faruqi & Faruqi Investigates Vistagen Investors' Claims Ahead of March 2026 Deadline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Investor Claims Investigation: Faruq & Faruq LLP is investigating potential claims against Vistagen Therapeutics, Inc., particularly for investors who purchased securities between April 1, 2024, and December 16, 2025, aiming to protect their legal rights and provide support.
- Litigation Deadline: Investors must apply to become lead plaintiffs in a federal securities class action by March 16, 2026, as missing this deadline may result in the loss of claims, underscoring the importance of timely action.
- Legal Consultation Channels: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 to discuss legal options and obtain further information.
- Market Reaction Expectations: This investigation may negatively impact Vistagen's stock price, prompting investors to monitor developments closely to adjust their investment strategies and mitigate potential losses.
Analyst Views on VTGN
Wall Street analysts forecast VTGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTGN is 15.50 USD with a low forecast of 12.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.671
Low
12.00
Averages
15.50
High
19.00
Current: 0.671
Low
12.00
Averages
15.50
High
19.00
About VTGN
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
